PreveCeutical Medical
Vancouver-based public health sciences company (CSE: PREV) developing preventive and curative therapies through five R&D programs spanning a Sol-Gel nose-to-brain drug delivery platform, nature-identical peptides from Caribbean Blue Scorpion venom, non-addictive analgesics, gene therapy for metabolic disorders, and a concussion therapeutic, with one direct-to-consumer supplement (CELLB9) commercially available.
- Company typePublic
- Founded2015
- HeadquartersVancouver, Canada
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What PreveCeutical Medical does
PreveCeutical Medical Inc. is a Vancouver-based health sciences company founded in 2015 and publicly traded on the Canadian Securities Exchange (CSE: PREV), OTCQB (PRVCF), and Frankfurt Stock Exchange (FSE: 18H). The company develops preventive and curative therapies using organic and nature-identical products, organized around five R&D programs: (1) the Sol-Gel Platform, an adaptable water-based formulation using FDA-approved excipients designed for controlled, sustained nose-to-brain drug delivery that bypasses the blood-brain barrier; (2) the BSV Peptide Program, screening nature-identical peptides derived from Caribbean Blue Scorpion venom, with four lead peptides identified that inhibit glioblastoma-relevant target proteins; (3) a Non-Addictive Analgesic program developing cyclic peptide analogues of dynorphin with proprietary disulfide linker stabilization; (4) a Dual Gene Therapy program using smart-siRNA constructs for diabetes and obesity; and (5) a Concussion Therapeutic Product for mild traumatic brain injury.
The company's commercial operations consist of a single consumer product, CELLB9, an oral solution derived from Blue Scorpion serum and marketed as an immune system booster, sold directly to health-conscious consumers via its own e-commerce platform since June 2016. There is no disclosed unit volume or retail pricing. A secondary business model is pharmaceutical co-development and licensing, with named partners including UniQuest Pty Ltd and The University of Queensland (joint patent owners of cyclic peptide pain therapy IP), Endosane Pharmaceuticals (Sol-Gel CBD/COVID-19 work), Asterion (option for up to 51% in Sol-Gel IP), and BioGene Therapeutics (gene therapy spin-off effective November 2025). PreveCeutical (Australia) Pty Ltd, established in 2018, supports R&D operations and accesses Australia's 43.5% R&D tax cashback incentive, having received AU$1.2 million and AU$315K in incentive refunds in August 2020 and August 2021 respectively.
PreveCeutical operates with a lean organization (11-50 employees) anchored by an advisory bench of senior pharmaceutical executives (former Pfizer, J&J/Janssen, Novartis, Genentech, Ultragenyx). The company has funded operations through a CAD $1 million convertible debt facility from the CEO in 2016 and a series of small non-brokered private placements from 2024 through 2026, totaling over CAD $3.3 million across multiple tranches. The company has experienced acute capital constraints, including a Management Cease Trade Order from the British Columbia Securities Commission in May 2024 due to delayed financial filings caused by lack of funds. Revenue is not publicly disclosed, and the company is best characterized as a pre-revenue biotech sustaining a preclinical R&D portfolio through periodic dilutive financings.
PreveCeutical Medical firmographics
Firmographics- Name
- PreveCeutical Medical
- Legal name
- PreveCeutical Medical Inc.
- Website
- http://preveceutical.com/
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Vancouver-based public health sciences company (CSE: PREV) developing preventive and curative therapies through five R&D programs spanning a Sol-Gel nose-to-brain drug delivery platform, nature-identical peptides from Caribbean Blue Scorpion venom, non-addictive analgesics, gene therapy for metabolic disorders, and a concussion therapeutic, with one direct-to-consumer supplement (CELLB9) commercially available.
- Ownership category
- akta.pro rank
PreveCeutical Medical industry classification
Industry- Product category
- Biopharmaceutical R&D
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where PreveCeutical Medical is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
PreveCeutical Medical business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- CELLB9 Product Sales: Sale of CELLB9, an oral solution containing polarized and potentiated essential minerals extracted from a peptide derived from Caribbean Blue Scorpion serum, marketed as an immune system booster. Sold directly to health-conscious consumers. The product has been available for sale since June 2016.
- R&D Services and Co-Development: Revenue through R&D collaborations, co-development agreements, and option/license fees from pharmaceutical partners seeking to use PreveCeutical's proprietary platforms (Sol-Gel, peptide technologies) for their therapeutic programs.
- Intellectual Property Licensing and Royalties: Future potential licensing revenue from patented technologies including cyclic peptide pain therapies, CNS-active agent delivery, and Sol-Gel platform. PreveCeutical has granted Asterion an option to purchase up to 51% interest in Sol-Gel IP.
- Government R&D Tax Incentives: PreveCeutical (Australia) Pty Ltd has received Australian R&D tax incentive cash refunds, including AU$1,227,902 in August 2020 and AU$315,338 in August 2021, supporting ongoing research activities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | CELLB9 consumer supplement product sold directly to health-conscious consumers |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
PreveCeutical Medical product offering
Product offeringCore offering
PreveCeutical Medical is a health sciences company developing innovative preventive and curative therapies. It operates a research pipeline built on proprietary drug delivery (Sol-Gel nose-to-brain platform), peptide therapeutics derived from Caribbean Blue Scorpion venom (BSV Peptide Program), non-addictive analgesic peptides, dual gene therapy for diabetes and obesity, and a concussion therapeutic product. It also sells CELLB9™, an oral supplement marketed as an immune system booster, directly to consumers.
Product overview
PreveCeutical Medical Inc. is a health sciences company developing innovative options for preventive and curative therapies utilizing organic and nature-identical products. The company's portfolio consists of multiple R&D programs including: the Sol-Gel Platform (a nose-to-brain drug delivery system), the BSV Peptide Program (screening Caribbean Blue Scorpion venom-derived peptides for cancer applications), the Non-Addictive Analgesic Program (developing opioid alternatives), Dual Gene Therapy for diabetes and obesity, and a Concussion Therapeutic Product. The company also previously commercialized CELLB9™ as an oral solution derived from Blue Scorpion venom. PreveCeutical operates through its Canadian parent company and PreveCeutical (Australia) Pty Ltd. subsidiary.
Differentiator
Problem solved
Functional benefit
Brands
- CELLB9: Oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Blue Scorpion serum, marketed as an immune system booster.
- Nature Identical™
Products and services
- CELLB9™ Oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion serum, marketed as an immune system booster for health-conscious consumers. Sold directly to consumers via the company website.
- Sol-Gel Platform Adaptable water-based formulation using FDA-approved excipients that enables controlled and sustained drug delivery directly to the brain by bypassing the blood-brain barrier via nose-to-brain delivery. Licensed/co-developed with pharmaceutical partners.
- BSV Peptide Program Research program screening and synthesizing nature-identical peptides derived from Caribbean Blue Scorpion venom for therapeutic applications, with initial focus on identifying lead peptides that inhibit target proteins in aggressive brain cancers such as glioblastoma.
- Non-Addictive Analgesic Research program developing non-addictive analgesic peptides as replacements for highly addictive analgesics such as morphine, fentanyl, and oxycodone, using proprietary disulfide linker technology to enhance peptide stability while maintaining potency.
- Dual Gene Therapy Program Research program developing gene therapy for curative and prevention therapies for diabetes and obesity using smart-siRNA constructs, one of the company's five R&D programs.
- Concussion Therapeutic Product Therapeutic product in development for treating athletes who suffer from concussions (mild traumatic brain injury), one of the company's five R&D programs.
- Nature Identical™ Peptides Synthesized peptides derived from Caribbean Blue Scorpion venom that are nature-identical to the active compounds found in the venom, targeting various therapeutic applications.
Quantifiable outcome
- Four lead peptides identified from Caribbean Blue Scorpion venom that inhibit target proteins in glioblastoma cell-based assays, equally or more potent compared to Chlorotoxin
- +2 more outcomes
Companies that use PreveCeutical Medical
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
PreveCeutical Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
PreveCeutical Medical partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- The University of QueenslandcoreJoint ownership of Canadian Patent Application No. 3127020 for cyclic peptide pain therapy technology. The University of Queensland's School of Pharmacy collaborates on peptide library synthesis, pharmacological evaluation, and pharmacokinetic assessment for the non-addictive analgesic program. Research led by Dr. Harry Parekh in conjunction with collaborators at UQ's School of Pharmacy.
- BioGene Therapeutics Inc.corePreveCeutical is a significant shareholder of BioGene Therapeutics, a Texas-based life sciences company focused on gene-based treatments for metabolic disorders including diabetes and obesity. A Plan of Arrangement was completed on November 25, 2025, distributing 12 million BioGene shares to PreveCeutical shareholders, creating two focused entities. BioGene Australia operates as a wholly-owned subsidiary in Queensland.
- Endosane PharmaceuticalsminorLicense option agreement signed with Endosane Pharmaceuticals. Collaborative work on preclinical approaches to assess brain availability of CBD and pharmacologically relevant doses following intranasal CBD application.
- Asterion Cannabis Inc.minorAsterion granted an option to purchase up to 51% interest in PreveCeutical's Sol-Gel intellectual property. Development agreement for medicinal cannabinoid products using the Sol-Gel delivery system. Asterion is a private firm developing medical CBD products.
- UniQuest Pty LtdcorePreveCeutical signed a Research and Option Agreement with UniQuest Pty Ltd for the development of non-addictive analgesic peptides and peptide library synthesis. UniQuest is the main research partner for the BSV Peptide Program as well. UniQuest is the commercialization company of The University of Queensland, Australia, providing access to academic research expertise and the 43.5% Australian R&D tax incentive.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
PreveCeutical Medical competitors and assessment
Company assessmentDirect peers
- Karyopharm Therapeutics: Oncology-focused pharmaceutical company developing novel therapies for cancer including CNS malignancies. Comparable to PreveCeutical's BSV peptide oncology pipeline and brain cancer drug delivery strategy.
- Tetra Bio-Pharma: Canadian biopharmaceutical company developing cannabinoid-based therapeutics for pain, inflammation, and oncology. Directly comparable to PreveCeutical's cannabinoid Sol-Gel formulations and CBD-related antiviral programs.
- TFF Pharmaceuticals: Clinical-stage biopharmaceutical company using Thin Film Freezing technology to develop novel drug formulations and delivery systems. Comparable to PreveCeutical's Sol-Gel formulation platform for enabling differentiated drug delivery.
- Cara Therapeutics: Clinical-stage biopharmaceutical company developing non-opioid kappa opioid receptor agonists for acute pain and pruritus. Directly comparable to PreveCeutical's non-addictive analgesic program targeting opioid alternatives.
- Diffusion Pharmaceuticals: Biopharmaceutical company developing treatments for glioblastoma multiforme (GBM) and other solid tumors. Comparable to PreveCeutical's BSV peptide program targeting aggressive brain cancers including glioblastoma.
- Cyclenium Pharma: Discovery platform company specializing in cyclic peptides and macrocycles with applications in pain and CNS disorders. Directly comparable to PreveCeutical's cyclic peptide pain therapy program built on dynorphin analogues with proprietary linker technology.
Broad incumbents
- Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management, which acquired Impel NeuroPharma (developer of intranasal drug delivery for CNS disorders). Comparable to PreveCeutical's Sol-Gel nose-to-brain platform and non-opioid pain positioning at a much larger scale.
- PeptiDream: Japanese biopharmaceutical company with industry-leading peptide discovery platform, particularly for constrained/cyclic peptides. Comparable to PreveCeutical's peptide programs at a much larger and more established scale.
Emerging players
- Aptose Biosciences: Clinical-stage Canadian oncology company developing targeted therapies for hematologic malignancies and solid tumors. Comparable to PreveCeutical as a small-cap Canadian biotech with multiple oncology-relevant programs.
Regional players
- Acerus Pharmaceuticals: Canadian specialty pharmaceutical company focused on urology, endocrinology, and men's health. Comparable to PreveCeutical as a small-cap Canadian public health sciences company navigating capital markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
PreveCeutical Medical social profiles
Digital presencePreveCeutical Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
PreveCeutical Medical leadership team
Management profileNumber of profiles
Profiles10 records
PreveCeutical Medical subsidiaries and ownership
Company hierarchySubsidiaries2 records
PreveCeutical Medical funding detail
Funding detailFunding overview
Funding rounds7 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PreveCeutical Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PreveCeutical Medical
What does PreveCeutical Medical do?
PreveCeutical Medical is a health sciences company developing innovative preventive and curative therapies. It operates a research pipeline built on proprietary drug delivery (Sol-Gel nose-to-brain platform), peptide therapeutics derived from Caribbean Blue Scorpion venom (BSV Peptide Program), non-addictive analgesic peptides, dual gene therapy for diabetes and obesity, and a concussion therapeutic product. It also sells CELLB9™, an oral supplement marketed as an immune system booster, directly to consumers.
Is PreveCeutical Medical a public or private company?
PreveCeutical Medical is a public company. It is classified as public and is currently operating.
When was PreveCeutical Medical founded?
PreveCeutical Medical was founded in 2015. It employs 1 to 10 people.
Where is PreveCeutical Medical based?
PreveCeutical Medical is headquartered in Vancouver, Canada, in the North America region.
How does PreveCeutical Medical make money?
Four revenue lines are on record. CELLB9 Product Sales are the primary driver. The others are R&D Services and Co-Development, intellectual Property Licensing and Royalties and government R&D Tax Incentives.
Who are PreveCeutical Medical's main competitors?
Direct peers on record are Karyopharm Therapeutics, Tetra Bio-Pharma, TFF Pharmaceuticals, Cara Therapeutics, Diffusion Pharmaceuticals and Cyclenium Pharma. Broad incumbents are Collegium Pharmaceutical and PeptiDream. Aptose Biosciences is listed as an emerging player. Acerus Pharmaceuticals is listed as a regional player.
Does PreveCeutical Medical have an API?
No public API is recorded for PreveCeutical Medical.
What industry is PreveCeutical Medical in?
PreveCeutical Medical's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.